4.5 Review

Epstein-Barr virus and multiple sclerosis. From evidence to therapeutic strategies

期刊

JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 361, 期 -, 页码 213-219

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2016.01.013

关键词

Multiple sclerosis; Epstein-Barr virus; Human endogenous retroviruses; B-cell; CD20

资金

  1. Basque Country Foundation for Health Innovation and Research
  2. Bayer-Schering
  3. Biogen Idec
  4. Merck Seron
  5. Novartis
  6. UCB
  7. Almirall
  8. Teva

向作者/读者索取更多资源

Multiple sclerosis is caused by a complex interaction between genetic predisposition and environmental factors. Epstein Barr virus (EBV) is an environmental risk factor that is strongly related to multiple sclerosis (MS), since EBV seropositivity is linked to a significant risk of developing MS. EBV may be involved in the pathogenesis of the disease and it is possibly a prerequisite for the development of MS. EBV infection persists in B-cells during the lifetime of the host and can modulate their function. In addition, MS patients might have a deficient capacity to eliminate latent EBV infection in the central nervous system and this would promote the accumulation of infected B cells. Several mechanisms of pathogenesis, including a direct and indirect function of infected B cells, have been postulated in inflammation and neurodegeneration. A relationship between EBV and human endogenous retroviruses in the pathogenesis of MS has also been reported. If EBV is important in the pathogenesis of MS, different therapeutic strategies seem possible for MS treatment. (C) 2016 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据